SynapDx and the Broad Institute of Harvard and MIT have joined forces to take on the area of autism diagnostics using next-generation sequencing.
Startup SynapDx will team with the famed Broad Institute of Harvard and MIT to advance next-generation DNA sequencing for more accurate and clinically useful autism diagnostic tools.
Believe us when we tell you this: The 15 fiercest medical device and diagnostics companies of 2013 rival our first annual roundup from 2012 in terms of innovation, drive and market-changing...
SynapDx has wrapped up $15.4 million in new funding to help advance a 660-patient study of the company's autism blood test that began enrollment in April. The Massachusetts startup turned to Google Ventures to lead the round.
SynapDx is allying with gene sequencer Illumina to explore development of diagnostic tools for autism spectrum disorders and other "opportunities in neurodevelopment."
A team of Canadian and U.S. researchers believe they've come up with a possible blood test option for autism, something that could help spot a unique pattern of fat metabolism blood markers found in a sizeable minority of children with the disorder.
SynapDx, developer of a blood diagnostic test for autism spectrum disorders, nailed down $6 million in new venture funding, the company disclosed Dec. 11. Having the financial backing enables executives to proceed with a 600-patient prospective multicenter clinical study for the test.
SynapDx plans to begin clinical trials early next year for a blood test that could lead to the early detection of autism.
California-based Altura Medical has rounded up $20 million in Series A financing. The early-stage manufacturer is developing devices and methods for the treatment of abdominal aortic aneurysms, a